<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04496336</url>
  </required_header>
  <id_info>
    <org_study_id>NOISE-AF</org_study_id>
    <nct_id>NCT04496336</nct_id>
  </id_info>
  <brief_title>Non-invasive Substrate Evaluation in Atrial Fibrillation</brief_title>
  <acronym>NOISE-AF</acronym>
  <official_title>Non-invasive Substrate Evaluation in Atrial Fibrillation Using Cardiac Magnetic Resonance and Electrocardiographic Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gregorio Mara침칩n Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to assess the right and left atrial electrophysiological substrate in atrial&#xD;
      fibrillation patients using the invasive electroanatomic map (basal and with extraestimulus)&#xD;
      as well as its correlation with cardiac magnetic resonance and electrocardiographic imaging.&#xD;
      The results will also be compared when the patient is in sinus rhythm and atrial&#xD;
      fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2020</start_date>
  <completion_date type="Anticipated">January 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between conduction velocity and MRI fibrosis.</measure>
    <time_frame>Baseline</time_frame>
    <description>The conduction velocity in sinusal rhythm and with extra estimuli will be correlated with the MRI late gadolinium enhancement sequence (MRI-LGE).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between voltage and MRI fibrosis.</measure>
    <time_frame>Baseline</time_frame>
    <description>The voltage in sinus rhythm and in atrial fibrillation will be correlated with the MRI-LGE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between electrocardiographic image (ECGi) and MRI-LGE.</measure>
    <time_frame>Baseline</time_frame>
    <description>The xxx of the ECGi will be correlated with the MRI-LGE.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>C14.280.067.198</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with persistent or paroxysmal atrial fibrillation, without cardiomyopathy (LVEF&gt;&#xD;
        40%) or significant valvulopathy who will undergo first AF ablation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Atrial fibrillation paroxysmal or persistent with criteria for percutaneous ablation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiomiopathy (FEVI&lt;40%) or significant valvulopathy.&#xD;
&#xD;
          -  MRI not possible or contraindicated.&#xD;
&#xD;
          -  Previous atrial fibrillation ablation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Gregorio Mara침on</name>
      <address>
        <city>Madrid</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Atienza, MD, PhD</last_name>
      <phone>+34915868286</phone>
      <email>felipeatienza@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lluis Mont, MD, PhD</last_name>
      <phone>+3493227551</phone>
      <email>lmont@clinic.ub.es</email>
    </contact>
    <contact_backup>
      <last_name>Mont</last_name>
    </contact_backup>
    <investigator>
      <last_name>Lluis Mont, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gala Caixal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduard Guasch, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roger Borras, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Alarc칩n, B Eng</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paz Garre, B Eng</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivo Roca, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Maria Tolosana, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2020</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Josep Lluis Mont Girbau</investigator_full_name>
    <investigator_title>Head of Arrythmia Unit</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Paroxysmal Atrial Fibrillation</keyword>
  <keyword>Persistent Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

